Since S100A6 consistently demonstrated higher levels in all three lines we tested, we sought to determine the role of S100A6 in HER2-overexpressing breast cancer cells and in EGF/EGFR cell signaling through siRNA knockdown experiments. This evidence concerns the gene ERBB2 and breast cancer.